Triamcinolone Acetonide 40Mg/Ml

Introduction Overview

Generic Name

triamcinolone acetonide 40mg/mL

Brand Name

Kenalog-40

Dosage Form

intra-articular/intramuscular injection

Drug Class

Glucocorticoids

Pharmacokinetics

Absorption:
Kenalog-40, containing triamcinolone acetonide, is administered primarily via intramuscular or intra-articular injection, providing a depot effect. After intramuscular injection, the drug is slowly absorbed into the systemic circulation, resulting in a prolonged duration of action. Intramuscular absorption occurs through muscle capillaries and lymphatics, with onset of systemic corticosteroid effects typically observed within hours to days, depending on dose and site of injection. Intra-articular administration results in local absorption at the joint space with slower systemic uptake, which provides focused anti-inflammatory action with reduced systemic exposure. The formulation as a suspension contributes to delayed systemic absorption and prolonged activity compared to oral corticosteroids.

Distribution:
After absorption, triamcinolone acetonide distributes extensively throughout body tissues. It binds moderately to plasma albumin and corticosteroid-binding globulin, allowing free active drug to reach target tissues. The drug crosses cell membranes easily due to its lipophilicity and accumulates in tissues with glucocorticoid receptors, such as muscle, skin, lungs, and immune cells. The volume of distribution is similar to other corticosteroids, with some sequestration in protein and fat compartments. Triamcinolone crosses the placenta and is excreted in breast milk, necessitating caution during pregnancy and lactation.

Metabolism:
Triamcinolone acetonide undergoes hepatic metabolism primarily via cytochrome P450 enzymes, particularly CYP3A4 isoenzyme pathways. It is converted into inactive metabolites through hydroxylation and conjugation reactions. Hepatic function significantly affects metabolism; impaired liver function may alter clearance and increase systemic exposure. The metabolic profile allows Kenalog-40 to maintain a relatively long half-life compared to other corticosteroids.

Elimination:
Elimination of triamcinolone acetonide and its metabolites occurs mainly via renal excretion. The biological half-life is approximately 2 to 5 hours, but the clinical duration of effect is prolonged because of the depot administration and sustained release. Complete elimination includes both the unmetabolized drug and conjugated metabolites via urine. The presence of benzyl alcohol as preservative requires consideration in neonates or patients with renal impairment due to potential toxicity from accumulation.

Dosage Forms

Available Dosage Forms:
Kenalog-40 is available as an injectable suspension formulation containing 40 mg/mL of triamcinolone acetonide. It comes in multiple vial sizes including 1 mL, 5 mL, and 10 mL vials. The formulation contains inactive ingredients such as benzyl alcohol (as preservative), sodium chloride for isotonicity, carboxymethylcellulose sodium, polysorbate 80, sodium hydroxide, hydrochloric acid, and nitrogen to maintain stability and uniform suspension. The product must be shaken well prior to use to avoid clumping and ensure proper dosing.

Dosages for Adults and Adolescents:
Systemically (intramuscularly), the initial dose varies widely depending on the condition, ranging from 2.5 mg to 100 mg per day. A common initial dose is 60 mg injected deeply into the gluteal muscle, with maintenance doses adjusted between 40 mg to 80 mg as clinically indicated. Some patients may respond well to lower doses, such as 20 mg or less. For allergic conditions like hay fever or pollen asthma not responsive to conventional therapies, seasonal single injections of 40 mg to 100 mg may be effective.

Intra-articular administration involves local injections into joints or tendons. Initial doses range from 2.5 mg to 5 mg (up to 10 mg) for smaller joints, and 5 mg to 15 mg (up to 40 mg) for larger joints. Typically, a single injection is sufficient, but multiple injections may be administered based on therapeutic response.

Pediatric dosing (children and adolescents) is weight-based or surface area-based, with an initial dosage range of 0.11 to 1.6 mg/kg/day, divided into 3 or 4 doses, or 3.2 to 48 mg/m2 body surface area per day.

Specific Patient Populations:
In pediatric patients, Kenalog-40 requires caution due to potential bone growth inhibition and growth suppression. In neonates, use is limited or avoided due to benzyl alcohol preservative toxicity risk. Patients with infections, especially fungal infections or idiopathic thrombocytopenic purpura (ITP), may have contraindications. Dosage adjustments may be necessary in patients with hepatic or renal impairment due to altered metabolism and elimination. Pregnant or breastfeeding women should only use Kenalog-40 if benefits outweigh risks due to potential teratogenicity and effects on milk production.

The injectable suspension should never be administered intravenously to avoid severe adverse reactions, such as embolic events.

Mechanism Of Action

Kenalog-40 contains triamcinolone acetonide, a synthetic corticosteroid that mimics endogenous glucocorticoids. Its primary mechanism involves binding to cytoplasmic glucocorticoid receptors in target cells, forming a steroid-receptor complex. This complex translocates into the nucleus, where it modulates gene transcription by binding to glucocorticoid response elements on DNA. This genomic action results in upregulation of anti-inflammatory proteins and downregulation of pro-inflammatory genes, thereby reducing the synthesis of inflammatory mediators such as prostaglandins, leukotrienes, and cytokines.

At the cellular level, Kenalog-40 inhibits phospholipase A2 by inducing the production of lipocortin-1, which leads to decreased release of arachidonic acid, a precursor in inflammatory pathways. This action effectively diminishes the cascade responsible for inflammation and allergic responses. It also suppresses the migration of leukocytes and decreases capillary permeability, further reducing swelling and redness.

In addition to its anti-inflammatory effects, triamcinolone acetonide exerts immunosuppressive properties by inhibiting T-lymphocyte activation and proliferation, which is beneficial in autoimmune and hypersensitivity conditions. This immunomodulation can reduce pathologic immune responses but also increases susceptibility to infections.

Comparatively, Kenalog-40's mechanism aligns with other glucocorticoids like prednisone and methylprednisolone but differs in duration of action and potency due to the acetonide ester modification, which enhances lipophilicity, tissue penetration, and retention time at the injection site. Clinical studies demonstrate that intra-articular triamcinolone injections provide longer-lasting relief from joint inflammation compared to systemic corticosteroids, owing to slower absorption and sustained local effects. Overall, Kenalog-40's mechanism underpins its diverse use in inflammatory, allergic, autoimmune, and endocrine disorders.

Pharmacological Actions

Potent anti-inflammatory effect by inhibition of inflammatory mediator synthesis.
Immunosuppressive activity through modulation of T-cell function and cytokine production.
Reduction of edema and capillary permeability in inflamed tissues.
Suppression of allergic reactions by decreasing histamine release and leukocyte migration.
Modulation of carbohydrate, protein, and fat metabolism contributing to metabolic effects.
Inhibition of fibroblast proliferation and collagen deposition, impacting scar formation.
Anti-proliferative effects useful in certain dermatologic conditions.
Glucocorticoid receptor-mediated alteration of gene transcription leading to long-lasting effects.
Depot formulation providing sustained release and prolonged duration of action.
Decreased production of prostaglandins and leukotrienes by phospholipase A2 inhibition.
Suppression of hypothalamic-pituitary-adrenal (HPA) axis after systemic administration.
Stabilization of lysosomal membranes to reduce tissue damage during inflammation.
Reduction in migration and function of neutrophils and macrophages at inflammatory sites.
Decrease of capillary dilation and redness secondary to inflammatory processes.

Therapeutic Or Clinical Uses

Treatment of severe allergic reactions including anaphylaxis and asthma exacerbations.
Management of inflammatory and autoimmune skin disorders such as eczema and psoriasis.
Intra-articular injections for inflammatory joint diseases including rheumatoid arthritis and osteoarthritis.
Therapy for tendonitis, bursitis, and other musculoskeletal inflammatory conditions.
Treatment of inflammatory eye disorders like uveitis.
Management of severe colitis and other inflammatory bowel diseases.
Adjunct therapy in adrenal insufficiency and certain endocrine disorders.
Control of hematologic disorders such as idiopathic thrombocytopenic purpura (ITP).
Treatment of pulmonary inflammatory conditions, including sarcoidosis.
Local treatment of dermatologic lesions by intralesional injections.
Management of systemic lupus erythematosus and related autoimmune diseases when corticosteroid therapy is indicated.
Reduction of inflammation caused by severe insect bites and allergic dermatitis.
As a seasonal treatment for hay fever or pollen-induced asthma not responsive to standard therapies.
Treatment of nerve-muscle disorders such as myasthenia gravis, as adjunctive therapy.
Suppression of immune responses in transplantation or other immune-mediated conditions, off-label in select cases.

Side Or Adverse Effects

Local injection site reactions including pain, swelling, and possible tissue atrophy particularly with intramuscular injection in small muscles like the deltoid.
Increased risk of infection due to immunosuppression; may cause severe and potentially fatal viral and bacterial infections.
Hypersensitivity reactions including anaphylaxis, though rare.
Endocrine effects such as suppression of adrenal gland function and Cushingoid features with long-term use.
Osteoporosis, bone mineral density loss, and increased fracture risk during prolonged therapy.
Growth suppression in pediatric patients.
Ophthalmic complications including increased intraocular pressure, glaucoma, cataracts, and potential vision changes.
Gastrointestinal disturbances such as nausea, abdominal pain, peptic ulceration, gastrointestinal bleeding, and pancreatitis.
Neuropsychiatric effects including mood swings, depression, insomnia, and rarely psychosis or seizures.
Metabolic alterations including hyperglycemia, altered fat distribution, and electrolyte imbalances (e.g., hypokalemia, sodium retention).
Skin changes including acne, thinning, bruising, delayed wound healing, increased hair growth, or hair thinning.
Muscle weakness and myopathy especially with long term high-dose systemic therapy.
Fluid retention causing edema and hypertension.
Menstrual irregularities and reproductive system effects such as impotence or decreased libido.
Rare adverse event of increased intracranial pressure (pseudotumor cerebri).

Precautions

Must not be administered intravenously due to risk of embolic events from suspension formulation.
Use caution in patients with systemic infections, especially fungal infections and tuberculosis.
Avoid live or live-attenuated vaccines during and shortly after therapy owing to immunosuppressive effects.
Monitor blood pressure, blood glucose, and electrolyte levels during prolonged treatment.
Use the lowest effective dose for the shortest duration to minimize adverse effects.
Avoid rapid discontinuation after long-term therapy to prevent adrenal insufficiency; gradual tapering required.
Limit salt intake and consider potassium supplementation as corticosteroids can cause sodium retention and potassium loss.
Children require careful monitoring for growth suppression and bone health.
Patients with peptic ulcer disease, osteoporosis, glaucoma, or psychiatric disorders require close supervision.
Patients should avoid exposure to persons with contagious infections, such as chickenpox or measles.
Adjust dose cautiously in hepatic or renal impairment due to altered metabolism and clearance.
Pregnant women should only receive Kenalog-40 if benefits justify potential risk to the fetus.
Breastfeeding mothers should use with caution as the drug passes into human milk and may affect infant growth.
Ensure aseptic technique during injection to prevent local infections and abscess formation.
Patients should report signs of infection, allergic reactions, unusual bruising, or changes in vision promptly.

Warnings

Anaphylactic reactions have occurred rarely after corticosteroid injections.
Kenalog-40 contains benzyl alcohol, which may be toxic in neonates causing hypotension, metabolic acidosis, and risk of kernicterus.
Do not inject into small muscles such as deltoid to avoid local tissue atrophy; deep gluteal injection preferred for intramuscular administration.
Kenalog-40 is not suitable for acute stress situations; supplemental corticosteroid therapy may be needed during stress, surgery, or severe illness.
High doses are contraindicated for traumatic brain injury due to lack of efficacy and potential harm.
Use with caution in patients with idiopathic thrombocytopenic purpura (ITP) or active chronic infections.
Suppresses immune response, thereby increasing risk and severity of infections including viral illnesses like chickenpox and measles.
Rapid withdrawal after long-term use can cause adrenal crisis; tapering schedules must be followed.
Long-term use can cause ocular complications such as cataracts and glaucoma; regular eye examinations recommended.
Avoid concurrent use with live vaccines to prevent vaccine-derived infections.
Potential for adrenal suppression requires monitoring during and after cessation of therapy, for up to one year.
Use in pregnancy only if clearly needed due to teratogenicity observed in animal studies.
Avoid strenuous use of joints after intra-articular injections to prevent joint damage.
Patients exposed to chickenpox or measles should receive immediate medical attention due to increased risk of serious complications.
Avoid freezing or autoclaving the vial as it may damage drug integrity.

Contraindication

Known hypersensitivity or allergy to triamcinolone acetonide or any component of Kenalog-40 formulation.
Systemic fungal infections due to immunosuppressive effects.
Idiopathic thrombocytopenic purpura (ITP) when administered in certain contexts may be contraindicated.
Patients receiving live or live-attenuated vaccines during therapy.
Use of Kenalog-40 by intravenous route is absolutely contraindicated due to fatal embolic phenomena.
Known allergy to benzyl alcohol preservative, particularly in neonates or infants.
Use in individuals with systemic herpes simplex infections of the eye without appropriate antiviral coverage.
Patients with untreated serious infections or those with active tuberculosis not on appropriate therapy.
Individuals with hypersensitivity to any glucocorticoids.
Caution contraindicated in severe uncontrolled hypertension, diabetes mellitus, osteoporosis, and peptic ulcer disease without close monitoring.

Drug Interactions

Concomitant use with antibiotics or antifungal agents may alter steroid metabolism and efficacy.
Hormone therapies such as birth control pills or hormone replacement can interact and affect steroid levels.
Warfarin and other blood thinners (e.g., dabigatran) may have altered anticoagulant effects requiring monitoring.
Digoxin toxicity risk is increased when used with corticosteroids due to potential hypokalemia.
Concurrent diuretic use ('water pills') may exacerbate potassium loss and increase risk of hypokalemia.
Insulin or oral hypoglycemic agents may require dose adjustment as corticosteroids can induce hyperglycemia.
Antituberculosis drugs such as rifampin can increase metabolism of triamcinolone, reducing its efficacy.
Nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, ibuprofen, naproxen, diclofenac, and indomethacin, increase risk of gastrointestinal bleeding and ulceration when combined with corticosteroids.
Seizure medications such as phenytoin and carbamazepine may reduce steroid concentrations via enzyme induction.
Live vaccines are contraindicated due to suppression of immune response and risk of vaccine-derived infections.
CYP3A4 inhibitors like ketoconazole may increase systemic corticosteroid levels, enhancing toxicity.
Barbiturates and rifampin may reduce the therapeutic effect by inducing hepatic metabolism.
Vaccines efficacy may be reduced when administered concurrently with systemic corticosteroids.
Combination with potassium-depleting agents increases likelihood of electrolyte imbalances.
Use with agents causing QT prolongation requires caution due to potential cardiac risks.

Preparations Of The Drug

Kenalog-40 injectable suspension containing 40 mg/mL triamcinolone acetonide.
Available vial sizes: 1 mL, 5 mL, and 10 mL.
Formulated with preservatives including 0.99% (w/v) benzyl alcohol.
Inactive ingredients: sodium chloride, carboxymethylcellulose sodium, polysorbate 80, sodium hydroxide, hydrochloric acid, nitrogen.
Suspension must be shaken thoroughly before use to ensure uniformity.
Should be injected without delay once drawn into the syringe to preserve sterility and efficacy.
Stored at controlled room temperature (20°C–25°C), protected from light and not frozen.
Vial should not be autoclaved; heat exposure may degrade the product.
Administered via intramuscular and intra-articular routes exclusively.
Not suitable for intravenous administration.
Commercially produced by Bristol-Myers Squibb.
Other formulations related to triamcinolone acetonide include Kenalog-10 and topical forms like creams, ointments, and sprays.
Preservative benzyl alcohol limits its use in neonates and requires caution in sensitive populations.